文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

利福平与异烟肼复方肠溶片的设计与评价。

Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.

机构信息

School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.

出版信息

Pharm Dev Technol. 2013 Mar-Apr;18(2):401-6. doi: 10.3109/10837450.2012.659254. Epub 2012 Feb 18.


DOI:10.3109/10837450.2012.659254
PMID:22339279
Abstract

In order to improve the bioavailability of rifampicin (RIF) from rifampicin and isoniazid (INH) combination formulations, the physicochemical characteristics of RIF, stability of RIF in different pH buffers in the presence of INH, as well as the effect of particle size of RIF materials on the dissolution rate were investigated. On the basis of the above examinations, enteric-coated tablets for RIF and INH combinations were designed and prepared. RIF showed low solubility and high apparent distribution coefficient in the intestinal pH (pH 4.0-7.4). With the decrease in pH, the degradation of RIF increase and the presence of INH deepen the degradation. Enteric-coated tablets were prepared after grinding the RIF materials by dry granulation technique. The pharmacokinetics of RIF and INH of self-made enteric-coated tablets in dogs were studied by comparing with the reference tablets. The AUC(0-48) of RIF in both reference and test tablets were 304.77 ± 42.27 and 353.79 ± 31.63 µg·h·mL(-1), respectively. The AUC(0-48) of INH in both reference and test tablets were 17.14 ± 8.59 and 19.62 ± 10.57 µg·h·mL(-1), respectively. Enteric-coated tablets may minimize the decomposition of RIF in gastrointestinal tract and improve the bioavailability.

摘要

为了提高利福平(RIF)和异烟肼(INH)联合制剂中利福平的生物利用度,考察了利福平的物理化学性质、在 INH 存在下不同 pH 缓冲液中利福平的稳定性,以及利福平材料粒径对溶出速率的影响。在此基础上,设计并制备了利福平与 INH 的肠溶片剂。利福平在肠道 pH(pH4.0-7.4)下溶解度低,表观分布系数高。随着 pH 的降低,利福平的降解增加,INH 的存在加深了降解。通过干法制粒技术将 RIF 材料研磨后制备肠溶片剂。通过与参比片剂比较,研究了自制肠溶片剂在犬体内的利福平和 INH 的药代动力学。参比和试验片剂中利福平的 AUC(0-48)分别为 304.77±42.27 和 353.79±31.63µg·h·mL(-1)。参比和试验片剂中 INH 的 AUC(0-48)分别为 17.14±8.59 和 19.62±10.57µg·h·mL(-1)。肠溶片剂可以最大限度地减少利福平在胃肠道中的分解,提高生物利用度。

相似文献

[1]
Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.

Pharm Dev Technol. 2012-2-18

[2]
Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.

J Pharm Biomed Anal. 2014-11

[3]
Encapsulation of Rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with Isoniazid at acidic pH.

Int J Pharm. 2013-2-11

[4]
Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.

Eur J Pharm Biopharm. 2013-9-18

[5]
Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid.

Nanomedicine (Lond). 2014-8

[6]
Stability of rifampicin in dissolution medium in presence of isoniazid.

Int J Pharm. 1999-11-10

[7]
Formulation and statistical optimization of a novel crosslinked polymeric anti-tuberculosis drug delivery system.

J Pharm Sci. 2008-6

[8]
In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.

Eur J Pharm Biopharm. 2008-9

[9]
Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.

Int J Tuberc Lung Dis. 1999-7

[10]
Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads.

Drug Dev Ind Pharm. 1998-7

引用本文的文献

[1]
New Ionic Liquid Forms of Antituberculosis Drug Combinations for Optimized Stability and Dissolution.

AAPS PharmSciTech. 2025-1-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索